Detalhe da pesquisa
1.
An inducible hACE2 transgenic mouse model recapitulates SARS-CoV-2 infection and pathogenesis in vivo.
Proc Natl Acad Sci U S A
; 120(25): e2207210120, 2023 06 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37307455
2.
Pan-coronavirus fusion inhibitors to combat COVID-19 and other emerging coronavirus infectious diseases.
J Med Virol
; 95(1): e28143, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36098460
3.
SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors.
J Med Virol
; 95(3): e28641, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36890632
4.
Repurposing Navitoclax to block SARS-CoV-2 fusion and entry by targeting heptapeptide repeat sequence 1 in S2 protein.
J Med Virol
; 95(10): e29145, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37804480
5.
25-Hydroxycholesterol-Conjugated EK1 Peptide with Potent and Broad-Spectrum Inhibitory Activity against SARS-CoV-2, Its Variants of Concern, and Other Human Coronaviruses.
Int J Mol Sci
; 22(21)2021 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34769299
6.
SARS-CoV-2 Omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors.
Emerg Microbes Infect
; 12(1): 2178241, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36748716
7.
A Modified Fibronectin Type III Domain-Conjugated, Long-Acting Pan-Coronavirus Fusion Inhibitor with Extended Half-Life.
Viruses
; 14(4)2022 03 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-35458385
8.
A Palmitic Acid-Conjugated, Peptide-Based pan-CoV Fusion Inhibitor Potently Inhibits Infection of SARS-CoV-2 Omicron and Other Variants of Concern.
Viruses
; 14(3)2022 03 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35336956
9.
Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation.
Signal Transduct Target Ther
; 6(1): 288, 2021 07 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34326308
10.
Fusogenicity of SARS-CoV-2 BA.2.86 subvariant and its sensitivity to the prokaryotic recombinant EK1 peptide.
Cell Discov
; 10(1): 6, 2024 Jan 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38191587
11.
Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant.
Cell Res
; 32(4): 404-406, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35087243
12.
Lipopeptide-based pan-CoV fusion inhibitors potently inhibit HIV-1 infection.
Microbes Infect
; 23(8): 104840, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34022374
13.
Structure-based evidence for the enhanced transmissibility of the dominant SARS-CoV-2 B.1.1.7 variant (Alpha).
Cell Discov
; 7(1): 109, 2021 Nov 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34750362